Abstract | BACKGROUND: RESULTS: Among the 151 patients included, 84 received dexamethasone, all but one during the second wave. VAP occurred in 63% of patients treated with dexamethasone (DEXA+) and 57% in those not receiving dexamethasone (DEXA-) (p = 0.43). The cumulative incidence of VAP, considering death, duration of MV and late immunosuppression as competing factors was not different between groups (p = 0.59). A multivariate analysis did not identify dexamethasone as an independent risk factor for VAP occurrence. The occurrence of BSI was not different between groups (29 vs. 30%; p = 0.86). DEXA+ patients had more VFD at day-28 (9 (0-21) vs. 0 (0-11) days; p = 0.009) and a reduced ICU length of stay (20 (11-44) vs. 32 (17-46) days; p = 0.01). Mortality did not differ between groups. CONCLUSIONS:
|
Authors | Ines Gragueb-Chatti, Alexandre Lopez, Dany Hamidi, Christophe Guervilly, Anderson Loundou, Florence Daviet, Nadim Cassir, Laurent Papazian, Jean-Marie Forel, Marc Leone, Jean Dellamonica, Sami Hraiech |
Journal | Annals of intensive care
(Ann Intensive Care)
Vol. 11
Issue 1
Pg. 87
(May 31 2021)
ISSN: 2110-5820 [Print] Germany |
PMID | 34057642
(Publication Type: Journal Article)
|